A detailed history of Vanguard Group Inc transactions in Immunome Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 3,131,568 shares of IMNM stock, worth $29.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,131,568
Previous 2,921,212 7.2%
Holding current value
$29.7 Million
Previous $35.3 Million 29.53%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$11.7 - $16.51 $2.46 Million - $3.47 Million
210,356 Added 7.2%
3,131,568 $45.8 Million
Q2 2024

Aug 13, 2024

BUY
$11.54 - $22.11 $10.4 Million - $19.9 Million
901,474 Added 44.63%
2,921,212 $35.3 Million
Q1 2024

May 10, 2024

BUY
$11.01 - $27.34 $3.08 Million - $7.65 Million
279,712 Added 16.08%
2,019,738 $49.8 Million
Q4 2023

Feb 14, 2024

BUY
$7.3 - $10.73 $9.81 Million - $14.4 Million
1,343,697 Added 339.04%
1,740,026 $18.6 Million
Q3 2023

Nov 14, 2023

BUY
$6.17 - $9.16 $138,522 - $205,651
22,451 Added 6.0%
396,329 $3.31 Million
Q4 2022

Feb 10, 2023

BUY
$2.21 - $5.0 $426 - $965
193 Added 0.05%
373,878 $826,000
Q3 2022

Nov 14, 2022

BUY
$3.39 - $6.14 $10,675 - $19,334
3,149 Added 0.85%
373,685 $1.66 Million
Q1 2022

May 13, 2022

SELL
$3.88 - $13.99 $22,589 - $81,449
-5,822 Reduced 1.55%
370,536 $2.11 Million
Q4 2021

Feb 14, 2022

BUY
$12.96 - $23.44 $50,258 - $90,900
3,878 Added 1.04%
376,358 $4.88 Million
Q3 2021

Nov 12, 2021

BUY
$12.5 - $27.76 $879,850 - $1.95 Million
70,388 Added 23.3%
372,480 $9.07 Million
Q2 2021

Aug 13, 2021

BUY
$16.33 - $32.33 $4.93 Million - $9.77 Million
302,092 New
302,092 $5.23 Million

Others Institutions Holding IMNM

About Immunome Inc.


  • Ticker IMNM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,127,400
  • Market Cap $115M
  • Description
  • Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...
More about IMNM
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.